The development of targeted therapies in oncology relies heavily on identifying and characterizing potent inhibitors of key signaling pathways. Focal Adhesion Kinase (FAK) is a crucial enzyme involved in cell proliferation, migration, and survival, making it an attractive target for cancer treatment. 1,2,4,5-Benzenetetramine Tetrahydrochloride, also known as Y15, has emerged as a potent and selective FAK inhibitor. As a supplier of specialized research chemicals, we provide access to this compound and insights into its preclinical profile.

Preclinical studies are fundamental to understanding a drug candidate's potential. For Y15 (1,2,4,5-Benzenetetramine Tetrahydrochloride, CAS 4506-66-5), these studies have focused on its pharmacokinetics, metabolic stability, and toxicity. Research has shown that Y15, when administered intraperitoneally (IP) in mice at a dose of 30 mg/kg, is rapidly absorbed, reaching maximum plasma concentrations within a short period. This rapid absorption is a favorable characteristic for therapeutic agents.

Metabolic stability is another critical factor. Studies using mouse and human liver microsomes have indicated that Y15 undergoes relatively rapid metabolic turnover. This suggests that the compound is processed efficiently by the body's metabolic systems. Understanding these metabolic pathways is essential for optimizing dosing regimens and predicting drug interactions.

Regarding toxicity, preclinical assessments have provided valuable insights into Y15's tolerability. Single-dose maximum tolerated dose (MTD) studies via oral administration showed a dose of 200 mg/kg, while repeated-dose MTD studies indicated 100 mg/kg per day for seven days. Importantly, at doses of 30 mg/kg (IP for 28 days) and 100 mg/kg (PO for 7 days), no mortality or significant changes in body weight were observed. Furthermore, no drug-related adverse effects were noted in clinical chemistry, hematology, or histopathology of major organs at these evaluated doses. This suggests a favorable initial safety profile for Y15.

For research laboratories and pharmaceutical companies engaged in oncology research, access to well-characterized compounds like Y15 is vital. We are a reliable source to buy 1,2,4,5-Benzenetetramine Tetrahydrochloride for your research needs. Our commitment as a chemical supplier ensures you receive high-purity materials to support your drug discovery and development efforts. If you are looking to purchase this FAK inhibitor for your preclinical studies, please contact us for a quote.